Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
+$0.45 today
- Market cap
- $53.90M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
Volume 0.01M
Average 0.05M
XLO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Xilio Therapeutics, Inc.NASDAQ: XLO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.21M rose 44.0% year over year, ahead of the +5.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 24.5% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.
Context
- Stock-based compensation amounted to 15.9% of revenue in FY2025, down 85.6 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +44.0% holds above the trailing-twelve-month pace of +5.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.94M USD
- Year-over-year change
- +7.8%
- 4-year CAGR
- +8.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.94M | +7.8% |
| FY2024 | 2024-12-31 | 6.43M | -12.8% |
| FY2023 | 2023-12-31 | 7.38M | -12.4% |
| FY2022 | 2022-12-31 | 8.42M | +69.9% |
| FY2021 | 2021-12-31 | 4.96M | — |
Stock-Based Compensation vs competitors
How XLO compares with its peers on the latest reported figures
- XLO's LTM Mar 2026 stock-based compensation of $6.49M is the 3rd largest of the 4 companies compared; the peer median is $237K.
- Its year-over-year change of +5.8% is the 2nd highest of 4, against a peer median of -98.0%.
- Stock-based compensation amounts to 12.1% of revenue for XLO, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.79B | -27809.6% | +824.6% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $11.67M | +86.0% | +523.5% | — |
| LTM Mar 2026 | $6.49M | +5.8% | -6.3% | 12.1% | |
| LTM Jun 2026 | $237K | -98.0% | +48.7% | 0.7% | |
| Peer median (excluding XLO) | $237K | -98.0% | +523.5% | 0.7% | |
Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Depreciation & Amortization | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| Deferred Income Tax | 222K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.96M | 8.42M | 7.38M | 6.43M | 6.94M |
| Change in Working Capital | (11.8M) | 2M | (1.66M) | 31.78M | 25.13M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.82M) | 485K | (2.06M) | 1.53M | 152K |
| Other Working Capital | (8.99M) | 1.52M | 405K | 30.26M | 29.97M |
| Other Non-Cash Items | 173K | 224K | 160K | 3K | (3.56M) |
| Operating Cash Flow | (80.75M) | (75.72M) | (68.62M) | (18.38M) | (4.99M) |
| Capital Expenditures | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Debt Repayment | (110K) | (85K) | (6.75M) | (3.38M) | 0 |
| Common Stock Issued | 116.36M | 16K | 202K | 6.83M | 87.78M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (467K) | 0 | 0 | 25.75M | 0 |
| Financing Cash Flow | 260.67M | (69K) | (6.55M) | 29.2M | 87.78M |
| Effect of Forex Changes | 0 | (9K) | (25K) | 0 | 0 |
| Net Change in Cash | 178.82M | (77.67M) | (75.68M) | 10.78M | 82.27M |
| Free Cash Flow | (81.85M) | (77.59M) | (69.11M) | (18.41M) | (5.51M) |
Xilio Therapeutics, Inc.
NASDAQ:XLO
Intrinsic Alpha fair value
Locked
Current Price
$7.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.